Listen To Story Above
The evolution of GLP-1 receptor agonists has transformed diabetes and weight management treatment since 2005, marking significant advances in metabolic health therapies.
The FDA’s approval of Exenatide (Byetta) in 2005 launched this innovative drug class, followed by several breakthrough medications. Liraglutide (Victoza) emerged in 2010, while 2017 saw Semaglutide’s introduction through Ozempic and oral Rybelsus. By 2022, Tirzepatide (Mounjaro) advanced the field as a dual-receptor agonist.
These medications effectively regulate blood sugar and control appetite, though they typically require injection administration, professional medical supervision, and continuous prescription renewals.
GLP1 receptor agonists are looking like longevity drugs. A new study reports that drug-induced improvements in bone mass are mediated by the NAD-dependent SIRT1 enzyme.
If so, could NAD boosters work with GLP-1 drugs? Some thoughts…🧵 pic.twitter.com/6LXgnwHTVy— David Sinclair (@davidasinclair) March 12, 2025
The latest development in this field is Retatrutide (LY3437943), an advanced therapeutic agent targeting three distinct receptors. This triple-action approach combines GLP-1’s appetite and glucose management properties with GIP’s insulin sensitivity enhancement and glucagon’s fat-burning capabilities.
While injectable Retatrutide demonstrates promising results in clinical trials, many patients seek alternative delivery methods for their weight management needs.
Responding to this demand, The Wellness Company has developed DROP, an oral Retatrutide formulation. This innovative product utilizes liposomal technology to maximize absorption, offering a needle-free alternative for those pursuing weight management solutions.
Can GLP-1 Agonists Treat Alcohol Use Disorder?
Swedish registry study shows GLP-1 receptor agonists reduced alcohol-related hospitalizations by 33% vs non-treatment periods in 8K patients with alcohol disorders over 8.8 years.https://t.co/xMhMW8sXvx pic.twitter.com/l5mFKTgGHo
— Psychopharmacology Institute (@PsychopharmInst) March 24, 2025
DROP represents a convenient option for individuals interested in GLP-1 therapy benefits without injection requirements, providing a more accessible approach to weight management support.
This advancement offers a streamlined solution for those seeking metabolic health support through a simplified delivery method.
